[關鍵詞]
[摘要]
目的 研究箭葉淫羊藿Epimedium sagittatum正丁醇部位黃酮類化學成分及其潛在抗肺纖維化活性。方法 運用硅膠、凝膠Sephadex LH-20、MCI、大孔吸附樹脂等多種柱色譜技術分離得到單體化合物，根據(jù)其理化性質結合波譜學技術對其結構進行鑒定。采用MTT法檢測化合物對轉化生長因子-β1（transforming growth factor β1，TGF-β1）誘導BEAS-2B細胞損傷的保護作用，初步探討其潛在抗肺纖維化活性。結果 從箭葉淫羊藿正丁醇部位分離得到了16個化合物，分別鑒定為5,7-二羥基-4′-甲氧基-黃酮-[3-O-α-L-鼠李糖基-(1→2)-α-L-鼠李糖苷]（1）、8-異戊烯基山柰酚（2）、淫羊藿次苷-Ⅰ（3）、sagittasine C（4）、5-hydroxy-4'-methoxy-8-(2-hydroxy-3-methyl-3-butenyl) flavone 3-O-α-L-rhamnopyranosyl-7-O-β-D-glucopyranoside（5）、anhydroicaritin-3-O-glucosyl 7-O-glucoside（6）、hexandraside E（7）、箭藿苷B（8）、sutchuenmedin B（9）、二葉淫羊藿苷B（10）、朝藿定C（11）、槲皮素（12）、金絲桃苷（13）、myricitrin（14）、(＋)-兒茶素（15）、(−)-表兒茶素（16）。結論 化合物1為新化合物，命名為箭藿苷D；化合物2、5～7、9、14～16均首次從箭葉淫羊藿中分離得到，其中化合物8和16能顯著提高TGF-β1誘導的BEAS-2B損傷細胞的活力，具有潛在抗肺纖維化活性。
[Key word]
[Abstract]
Objective To study the chemical constituents of n-butanol part of Epimedium sagittatum and their anti-pulmonary fibrosis activity. Method The chemical components were isolation and purification by modern column chromatography, and their structures were identified by spectrography techniques. The anti-pulmonary fibrosis activity of these compounds from E. sagittatum were evaluated by MTT on BEAS-2B cell damage induced by TGF-β1. Result Sixteen compounds were obtained from the E. sagittatum, which were identified as 5,7-dihydroxy-4′-methoxyflavone 3-O-α-L-rhamnosyl-(1→2)-α-L-rhamnoside (1), 8-prenylkaempferol (2), icariside I (3), sagittasine C (4), 5-hydroxy-4'-methoxy-8-(2-hydroxy-3-methyl-3-butenyl) flavone 3-O-α-L-rhamnopyranosyl-7-O-β-D-glucopyranoside (5), anhydroicaritin-3-O-glucosyl 7-O-glucoside (6), hexandraside E (7), sagittatoside B (8), sutchuenmedin B (9), diphylloside B (10), epimedin C (11), quercetin (12), hyperoside (13), myricitrin (14), (+)-catechin (15), (−)-epicatechin (16). Conclusion Compound 1 is a new compound, named epimedin D. Compounds 2, 5—7, 9, 14—16 were isolated from E. sagittatum for the first time, and compounds 7 and 15 significantly increased the viability of BEAS-2B cells induced by TGF-β1.
[中圖分類號]
R284.1
[基金項目]
國家重點研發(fā)計劃（中醫(yī)藥現(xiàn)代化研究重大專項）（2019YFC1708800）；河南省自然科學基金資助項目（252300420701）；河南省高等學校重點科研項目（24A360017）
